Thymosin Alpha 1
Tα1 / Thymalfasin
Thymosin Alpha 1 (Tα1 / Thymalfasin) is a healing & recovery research compound. Immune-modulating peptide that matures and balances T-cells and dendritic cells — tunes immunity up or down toward normal.
Thymosin Alpha 1 quick facts
| Reported research dosing | 0.5mg-2mg |
| Route | Subq |
| Cycle length | 4-12 Weeks |
| Frequency | 2-3x Weekly |
| Half-life | ~2 hrs |
| Forms | Injectable |
| Evidence level | Human (approved in some countries) |
Immune resilience with genuine clinical use abroad. One of the better-supported peptides.
How Thymosin Alpha 1 works
Immune-modulating peptide that matures and balances T-cells and dendritic cells — tunes immunity up or down toward normal.
Proposed benefits
Immune modulation and resilience.
Where to get Thymosin Alpha 1
Buy Thymosin Alpha 1 at AminoWell USA →Thymosin Alpha 1 reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Thymosin Alpha 1
Graded by what exists behind each claim.
✅ Clinically validated
- Approved as a drug in more than thirty countries (as Zadaxin) for hepatitis B and C and as an immune adjuvant, with randomized human trials behind those approvals. It has also been studied in sepsis, where a large Chinese randomized trial reported a mortality reduction.
- It is not FDA-approved in the United States and was moved to the FDA's restricted bulk-substances list, which is a regulatory position rather than a safety finding.
📊 Correlative data
- Long clinical use outside the US in immune-compromised patients and as a vaccine adjuvant. In the research community it is used for chronic infection and post-viral states, where the reported experience is gradual rather than dramatic — consistent with something that modulates immune signaling rather than suppressing or stimulating it outright.
🧪 Theoretical / extrapolated
- A thymic peptide that acts on Toll-like receptors to shift T-cell maturation — it pushes the immune system toward a more competent response rather than simply amplifying it.
- That bidirectional 'modulation' is the mechanistic claim, and it predicts the main caution: in autoimmune disease, nudging T-cell function is not obviously the direction you want, and nobody has tested it there.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Thymosin Alpha 1 actually does
Thymosin alpha 1 is a 28-residue acetylated peptide that your body already makes, and it is not a thymic hormone in the way the name implies. It is cleaved from prothymosin alpha, a nuclear protein present in essentially every cell, and its N-terminus is acetylated — which is not decoration. An acetyl cap removes the free alpha-amino group that aminopeptidases attack, and it is the reason a 3.1 kDa linear peptide with no disulfide bonds and no ring survives in plasma long enough to be a drug at all.
The receptor is a Toll-like receptor, and that single fact reorganizes the whole page. Thymosin alpha 1 signals through TLR9 on plasmacytoid dendritic cells and TLR2 on conventional dendritic cells and monocytes, recruiting MyD88 and activating NF-kappaB and interferon regulatory factors Tao 2023. TLR9 is the sensor for unmethylated bacterial and viral DNA. So this peptide is not a hormone telling T cells to mature; it is an agonist at the pattern-recognition machinery that tells the innate system an infection is present. Everything downstream — dendritic cell maturation, IL-12, type I interferon, and then the T-cell response those cytokines instruct — follows from that.
The T-cell effects are real and they are second-order. Mature dendritic cells present antigen and drive naive T cells toward Th1 differentiation; the peptide also reduces apoptosis of thymocytes and peripheral lymphocytes Dominari 2020. That is why the compound is described as maturing T cells — it does, by instructing the cells whose job is to instruct T cells.
Now the claim on this page's card that the evidence does not support. The card says it "tunes immunity up or down toward normal". The measured pharmacology is an agonist at innate sensors, and every trial endpoint that has moved has moved in the direction of restoring depressed immune function. The clearest of them is monocyte HLA-DR expression in sepsis Wu 2013: HLA-DR falls in sepsis-induced immunoparalysis, and the peptide raised it. Raising a suppressed system is not the same capability as lowering an overactive one, and no trial has shown the second. Calling it bidirectional is a description of a hope, not of a result.
Cell, rodent, human — and where it stops
Step one, mechanism: characterized, and unusually well. TLR9 and TLR2 engagement, MyD88 signaling, dendritic cell maturation, downstream cytokines Tao 2023 Dominari 2020. Named receptors, named adaptor, named transcription factors.
Step two, the largest randomized trial, and it is a good one. The ETASS trial Wu 2013 randomized 361 ICU patients with severe sepsis — 181 to intravenous thymosin alpha 1, 180 to control — and followed them for 28 days. Mortality was 26.0% with the peptide against 35.0% without it, P=0.049. Monocyte HLA-DR expression improved on days 3 and 7, which is the mechanism showing up in the same patients as the outcome. No serious drug-related adverse events were reported. A randomized 361-patient trial with a mortality endpoint puts this compound in a completely different evidential class from almost everything else in this Vault.
Step three, the systematic review, which is more measured. Liu 2016 pooled the randomized trials of thymosin alpha 1 in sepsis. The direction of effect is favorable; the caveats are the usual and the important ones — small individual trials, heterogeneity, and a literature concentrated in one region. A single P=0.049 in one trial is exactly the result that most often fails to replicate, and reading ETASS beside the review rather than alone is the honest way to hold it.
Step four, other populations. Linye 2021 reports improved postoperative survival after curative resection for solitary hepatitis B-related hepatocellular carcinoma, using propensity score matching — which is an observational design with statistical adjustment, not randomization. Tuthill 2023 is a pilot trial in renal dialysis patients, explicitly preliminary.
The obstacle, and it is the one that matters for the people reading this page. Every clinical trial of this peptide is in sick people. Sepsis, hepatitis B, cancer surgery, dialysis. The mechanism is the restoration of a suppressed innate response — which requires that the response be suppressed. There is no trial in healthy adults, and the mechanism gives no clear reason to expect one to be positive, because there is no immunoparalysis to reverse. That is the central unmade translation, and it is not a small one: it is the difference between the studied population and the buying population.
What would have to be true, and how you would know it was not
Three predictions, and they are unusually clean because this compound's mechanism has an ordinary blood test attached to it.
1. If it is doing what the trials showed, the lymphocyte compartment should move. The mechanism ends in dendritic cell maturation and T-cell expansion Tao 2023. So measure the T cells: a lymphocyte subset panel with CD4/CD8 and NK cell counts at baseline and at 8 weeks, on top of a CBC with differential for the absolute lymphocyte count. These are ordinary tests, they are the direct readout of the mechanism, and almost nobody using this compound orders them.
2. The prediction that cuts against the product: in a healthy person with a normal baseline, nothing should move. The peptide restores a depressed response Wu 2013. A person whose CD4 count, CD4/CD8 ratio and lymphocyte count are already normal has no deficit to correct, and the mechanistic expectation is a flat result. Printing that prediction is the point of this page. If it proves wrong — if healthy users reliably show a shift — that would be a genuinely new finding and worth recording.
3. Inflammatory tone should be watched, because a TLR agonist is not automatically anti-inflammatory. TLR2 and TLR9 engagement activates NF-kappaB, which is the master inflammatory transcription factor. hs-CRP at baseline and 8 weeks is the cheap index. A rise is not necessarily harm — it may be the mechanism working — but it is information, and someone with an autoimmune condition has a specific reason to want that number.
What nobody has tested yet
Four experiments nobody has run, and the first is the one the buying population needs.
Nobody has studied it in healthy adults. Every trial is in the critically ill or the chronically infected Wu 2013 Linye 2021 Tuthill 2023. A placebo-controlled study in healthy adults with lymphocyte subsets and vaccine response as endpoints would answer the question the market assumes has been answered, and it is not an expensive trial.
Nobody has tested it as a vaccine adjuvant in a modern trial. The mechanism — TLR agonism driving dendritic cell maturation Tao 2023 — is exactly how adjuvants work, and the readout is a straightforward antibody titer. This is the single most obvious application of the pharmacology and the cleanest possible test of whether it does anything in a person who is not sick.
Nobody has replicated ETASS outside its region. One 361-patient trial with P=0.049 Wu 2013 is a result that demands replication, and the systematic review Liu 2016 identifies exactly that gap. An independent multicenter trial would either establish this as a real sepsis therapy or close the question.
Nobody has published pharmacokinetics for subcutaneous dosing in the community pattern. The trial route is intravenous or clinic-administered subcutaneous on a defined schedule; the community uses smaller subcutaneous doses on schedules chosen by analogy. Whether those achieve anything like trial exposure has never been measured.
Thymosin Alpha 1 — its own safety story, not its class's
The class block above is written for immune peptides in general. Three things belong specifically to this one.
The safety record is genuinely good, and it comes from the right kind of study. A 181-patient exposure arm in critically ill people with no serious drug-related adverse events Wu 2013 is a far stronger safety statement than years of forum reports, because ICU patients are monitored continuously and adverse events are recorded systematically. Thymosin alpha 1 is licensed in a number of countries and has decades of clinical use behind it.
The mechanistic caution is autoimmunity, and it follows directly from the receptor. TLR9 agonism drives type I interferon production, and type I interferon is central to the pathogenesis of lupus and contributes to several other autoimmune conditions. Deliberately stimulating that axis in someone with an autoimmune disease is mechanistically the wrong direction, and it has not been studied in that population. Flagged as extrapolation from receptor biology, not as a reported harm. It is the reason the hs-CRP measurement above is not merely academic.
The transplant question is the same argument at higher stakes. Someone on immunosuppression after a transplant is taking drugs designed to prevent exactly the T-cell response this peptide promotes. No study has examined the combination, and the direction of the interaction is not in doubt even though its magnitude is.
What the good safety data does not cover. Duration. Trials run days to months in defined illnesses Wu 2013 Liu 2016. Continuous use for years in a well person is unstudied, and a chronically engaged innate sensor is not obviously neutral over that timescale. There is no evidence of harm; there is an absence of anyone having looked.
Sources read for this page
- Wu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Critical Care 2013 · PMID 23327199
- Liu F, et al. The efficacy of thymosin alpha1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infectious Diseases 2016 · PMID 27633969
- Dominari A, et al. Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology 2020 · PMID 33362999
- Tao N, et al. Thymosin alpha1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules 2023 · PMID 37110771
- Linye H, et al. Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis. Medicine (Baltimore) 2021 · PMID 34011034
- Tuthill CW, et al. A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report. International Immunopharmacology 2023 · PMID 36881981
Thymosin Alpha 1 — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Food is not a factor — pick a time you will keep
Nothing you eat touches a subcutaneous injection, so there is no meal to plan around. What does matter is a fixed slot: the commonest reason an injectable protocol underperforms is missed doses, not mistimed ones.
With a short half-life, dose it near the effect you want rather than at a fixed hour.
From half-life and route, not a dosing trial.
Thymosin Alpha 1 — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Thymosin Alpha 1 moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside Thymosin Alpha 1
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Complete Blood Count (CBC) with Differential | White cells and differential — the actual immune measurement |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Inflammation baseline |
| Vitamin D (25-Hydroxy) | The other immune input worth correcting first |
The Frequent Illness & Immune Resilience panel covers these in one order — 8 markers, $97.65 with the discount applied.
Check results you already have → · All 103 markers A–Z
Thymosin Alpha 1 — frequently asked questions
What is Thymosin Alpha 1?
Thymosin Alpha 1 (Tα1 / Thymalfasin) is a healing & recovery research compound. Immune-modulating peptide that matures and balances T-cells and dendritic cells — tunes immunity up or down toward normal.
What dosing does the research reference for Thymosin Alpha 1?
In the research literature, Thymosin Alpha 1 is referenced in the 0.5mg-2mg range, 2-3x Weekly. It is supplied as a lyophilized powder and reconstituted with acetic acid/bac water; the calculator above converts a research amount into syringe units. For research use only — not a recommendation for human use.
What is the half-life of Thymosin Alpha 1?
Thymosin Alpha 1 has an approximate half-life of ~2 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Thymosin Alpha 1?
Current evidence level: Human (approved in some countries). Thymosin Alpha 1 is offered for research purposes only and is not an approved medicine.
Thymosin Alpha 1 inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Thymosin Alpha 1 is used for
Thymosin Alpha 1 appears under 4 goals in the goal router.
Related Healing & Recovery compounds
Where this goes next
Thymosin Alpha 1 is the immune arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.